Clinical Trials Logo
  1. Home
  2. Peripheral Arterial Disease
  3. NCT03227822
  4. Details
NCT03227822 Clinical Trial

Short Spot Versus Long Lesion Stenting as Best Treatment for Extensive Occlusive SFA Disease

Peripheral Arterial Disease Clinical Trial

— STRONG  

Official title:
Short Spot Versus Long Lesion Stenting as Best Treatment for Extensive Occlusive SFA Disease; a Pilot Study

Clinical Trial Details — Status: Terminated

Administrative data
NCT number NCT03227822
Other study ID # STRONG SFA study
Secondary ID NL43610.060.13
Status Terminated
Phase N/A
First received
Last updated
Start date July 2013
Est. completion date February 1, 2015

Study information
Verified date October 2018
Source Catharina Ziekenhuis Eindhoven
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Since the length of lesion seems to be negatively associated with stent patency due to restenosis, it is thought that the efficacy of treatment in patients with multiple (> 1) short (focal; > 1 and < 5 cm) SFA lesions can be improved by spot stenting as compared to the use of one long stent. This study proposes to evaluate the endovascular treatment for patients with SFA lesions by comparing two strategies for patients with extensive occlusive SFA disease; 1) short spot (SS) stenting or 2) long lesion (LL) stenting.

Recruitment information / eligibility
Status Terminated
Enrollment 3
Est. completion date February 1, 2015
Est. primary completion date February 1, 2015
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- PAOD (ABI <0.90 and/or a decline of >0.15 after exercise test), Rutherford category 2, 3 or 4

- Multiple (>1) short (focal; >1 and < 5 cm) significant stenoses (= 50%) and/or occlusions in the superficial femoral artery

- Eligible for endovascular treatment via short spot stenting and via long lesion stenting according to international guidelines

- Unilateral occlusive disease

- Age = 18

Exclusion Criteria:

- Patients with PAOD Rutherford category 5 and 6

- Impaired inflow due to significant lesions in the arteries proximal to the SFA intended to treat

- Bilateral lesions with treatment indication

- Contra-indication for anticoagulant therapy

- Renal insufficiency (MDRD < 50 ml/min)

- Life expectancy < 6 months

- Known contrast allergy

- Pregnancy

- Unable to complete a questionnaire in the home language

Study Design

Related Conditions & MeSH terms

Intervention

Procedure:
• Short spot stenting

• Long lesion stenting

Locations
Country Name City State
n/a

Sponsors (1)
Lead Sponsor Collaborator
Catharina Ziekenhuis Eindhoven

Outcome
Type Measure Description Time frame Safety issue
Primary absence of binary restenosis (= 50% re-obstruction) of the target lesion without interval clinically driven reintervention 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT06032065 - Sequential Multiple Assessment Randomized Trial of Exercise for PAD: SMART Exercise for PAD (SMART PAD) Phase 3
Active, not recruiting NCT03987061 - MOTIV Bioresorbable Scaffold in BTK Artery Disease N/A
Recruiting NCT03506633 - Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients N/A
Active, not recruiting NCT03506646 - Dietary Nitrate Supplementation and Thermoregulation N/A
Active, not recruiting NCT04677725 - NEtwork to Control ATherothrombosis (NEAT Registry)
Recruiting NCT05961943 - RESPONSE-2-PAD to Reduce Sedentary Time in Peripheral Arterial Disease Patients N/A
Recruiting NCT06047002 - Personalised Antiplatelet Therapy for Patients With Symptomatic Peripheral Arterial Disease
Completed NCT03185052 - Feasibility of Outpatient Care After Manual Compression in Patients Treated for Peripheral Arterial Disease by Endovascular Technique With 5F Sheath Femoral Approach N/A
Recruiting NCT05992896 - A Study of Loco-Regional Liposomal Bupivacaine Injection Phase 4
Completed NCT04635501 - AbsorbaSeal (ABS 5.6.7) Vascular Closure Device Trial N/A
Recruiting NCT04584632 - The Efemoral Vascular Scaffold System (EVSS) for the Treatment of Patients With Symptomatic Peripheral Vascular Disease From Stenosis or Occlusion of the Femoropopliteal Artery N/A
Withdrawn NCT03994185 - The Merit WRAPSODY™ Endovascular Stent Graft for Treatment of Iliac Artery Occlusive Disease N/A
Withdrawn NCT03538392 - Serranator® Alto Post Market Clinical Follow Up (PMCF) Study
Recruiting NCT02915796 - Autologous CD133(+) Cells as an Adjuvant to Below the Knee Percutaneous Transluminal Angioplasty Phase 1
Active, not recruiting NCT02900924 - Observational Study to Evaluate the BioMimics 3D Stent System: MIMICS-3D
Completed NCT02901847 - To Evaluate the Introduction of a Public Health Approach to Peripheral Arterial Disease (PAD) Using National Centre for Sport and Exercise Medicine Facilities. N/A
Not yet recruiting NCT02455726 - Magnesium Oral Supplementation to Reduce Pain Inpatients With Severe Peripheral Arterial Occlusive Disease N/A
Not yet recruiting NCT02387450 - Reduced Cardiovascular Morbi-mortality by Sildenafil in Patients With Arterial Claudication Phase 2/Phase 3
Withdrawn NCT02126540 - Trial of Pantheris System, an Atherectomy Device That Provides Imaging While Removing Plaque in Lower Extremity Arteries N/A
Completed NCT02384980 - Saving Life and Limb: FES for the Elderly With PAD Phase 1